A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer

BMC Cancer

Julie E Bauman⁴  Keith D Eaton²  Sarah G Wallace²  Laurie L Carr⁶  Sang-Joon Lee¹  Dennie V Jones⁷  Hugo Arias-Pulido⁵  Lisa A Cerilli³  Renato G Martins² 

[1] Celltrion, Inc. Incheon, Korea

[2] Department of Internal Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA

[3] Department of Pathology, University of Michigan, Ann Arbor, MI, USA

[4] University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue, 5th floor, Pittsburgh, 15232, PA, USA

[5] Department of Internal Medicine, Divisions of Hematology/Oncology and Biostatistics, University of New Mexico Cancer Center, Albuquerque, New Mexico

[6] Division of Medical Oncology, National Jewish Health, Denver, CO, USA

[7] Department of Medicine, Division of Hematology/Oncology, University of Kentucky, Lexington, KY, USA

关键词: Vulnerable elder survey;    Frailty;    Platelet-derived growth factor;    Interstitial fluid pressure;    Elderly;    Paclitaxel;    Imatinib mesylate;    Non-small cell lung cancer;   

Others  :  1080160
DOI  :  10.1186/1471-2407-12-449

 received in 2012-06-08, accepted in 2012-10-02,  发布年份 2012

【 摘 要 】

Background

In non-small cell lung cancer (NSCLC), interstitial hypertension is a barrier to chemotherapy delivery, and is mediated by platelet derived growth factor receptor (PDGFR). Antagonizing PDGFR with imatinib may improve intra-tumoral delivery of paclitaxel, increasing response rate (RR).

Methods

This single-stage, open-label phase II study evaluated pulse dose imatinib and weekly paclitaxel in elderly patients with advanced NSCLC. Eligible patients were aged ≥ 70 with untreated, stage IIIB-IV NSCLC and ECOG performance status 0-2. Primary endpoint was RR. Secondary endpoints included median progression free and overall survival (PFS, OS) and correlatives of PDGFR pathway activation. Baseline Charlson Comorbidity Index (CCI) and Vulnerable Elder Survey-13 (VES-13) were correlated with outcomes.

Results

Thirty-four patients with median age 75 enrolled. Eleven of 29 (38%) were frail by VES-13 score. Overall RR was 11/34 (32%; 95% CI 17%-51%), meeting the primary endpoint. Median PFS and OS were 3.6 and 7.3 months, respectively. High tumoral PDGF-B expression predicted inferior PFS. Frail patients by VES-13 had significantly worse median PFS (3.2 vs. 4.5 months; p=0.02) and OS (4.8 vs. 12 months; p=0.02) than non-frail.

Conclusions

The combination of imatinib and paclitaxel had encouraging activity as measured by the primary endpoint of RR. However, PFS and OS were typical for elderly patients treated with single agent chemotherapy and the regimen is not recommended for further study. Adjunct imatinib did not overcome the established association of tumoral PDGF-B expression with inferior PFS. VES-13 was a powerful predictor of poor survival outcomes. Frailty should be further studied as a predictor of non-benefit from chemotherapy.

Trial Registration

ClinicalTrials.gov NCT01011075

【 授权许可】

   
2012 Bauman et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]George D: Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin Oncol 2001, 28(5 Suppl 17):27-33.
• [2]Ostman A, Heldin CH: Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res 2001, 80:1-38.
• [3]Jain RK: Transport of molecules in the tumor interstitium: a review. Cancer Res 1987, 47(12):3039-3051.
• [4]Heldin CH, Rubin K, Pietras K, Ostman A: High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004, 4(10):806-813.
• [5]Pietras K, Stumm M, Hubert M, Buchdunger E, Rubin K, Heldin CH, McSheehy P, Wartmann M, Ostman A: STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clinical cancer research: an official journal of the American Association for Cancer Research 2003, 9(10 Pt 1):3779-3787.
• [6]Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, Ostman A: Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002, 62(19):5476-5484.
• [7]Vlahovic G, Ponce AM, Rabbani Z, Salahuddin FK, Zgonjanin L, Spasojevic I, Vujaskovic Z, Dewhirst MW: Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br J Cancer 2007, 97(6):735-740.
• [8]Shikada Y, Yonemitsu Y, Koga T, Onimaru M, Nakano T, Okano S, Sata S, Nakagawa K, Yoshino I, Maehara Y, et al.: Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. Cancer Res 2005, 65(16):7241-7248.
• [9]Kawai T, Hiroi S, Torikata C: Expression in lung carcinomas of platelet-derived growth factor and its receptors. Laboratory investigation; a journal of technical methods and pathology 1997, 77(5):431-436.
• [10]Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Busund LT, Bremnes RM: Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 2008, 3(9):963-970.
• [11]Jain RK: 1995 Whitaker Lecture: delivery of molecules, particles, and cells to solid tumors. Ann Biomed Eng 1996, 24(4):457-473.
• [12]Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK: Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 1999, 59(15):3776-3782.
• [13]Taghian AG, Abi-Raad R, Assaad SI, Casty A, Ancukiewicz M, Yeh E, Molokhia P, Attia K, Sullivan T, Kuter I, et al.: Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2005, 23(9):1951-1961.
• [14]Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Lopez P, Anderson H, Gustafson N, Jeynes A, Gallant G, et al.: Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000, 92(13):1074-1080.
• [15]Fidias P, Supko JG, Martins R, Boral A, Carey R, Grossbard M, Shapiro G, Ostler P, Lucca J, Johnson BE, et al.: A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 2001, 7(12):3942-3949.
• [16]Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, Shinkai T, Sawa T, Goto I, Semba H, et al.: Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2006, 24(22):3657-3663.
• [17]American Joint Committee on Cancer (AJCC) Staging Manual 6th edition. Springer-Verlag, New York, NY; 2002.
• [18]Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216.
• [19]Malik SM, Moore DJ, Hwang JJ, Bahrani A, McGreivy J, Ramzi P, Egorin MJ, Min FD, McDougall K, Marshall JL: Pulse dose imatinib (Im) and weekly paclitaxel (P) phase I trial for advanced refractory solid tumors. ASCO Meeting Abstracts 2005, 23(16_suppl):3118.
• [20]Johnson FM, Tran HT, Prieto VG, Tamboli P, Peeples BO, Glisson BS: Phase I trial of imatinib mesylate (IM), cisplatin (P), and irinotecan (I) in small cell lung cancer (SCLC). ASCO Meeting Abstracts 2004, 22(14_suppl):7257.
• [21]Poplin E, Gharibo M, Rodriquez L, Elsayed Y, Wojtowicz M, Gounder M, Lagattuta T, Rubin E, Egorin M: Phase I study of imatinib mesylate and gemcitabine in patients with refractory solid tumor malignancy. ASCO Meeting Abstracts 2005, 23(16_suppl):3100.
• [22]Lilenbaum RC, Herndon JE, List MA, Desch C, Watson DM, Miller AA, Graziano SL, Perry MC, Saville W, Chahinian P, et al.: Single-agent versus combination chemotherapy in advanced non–small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2005, 23(1):190-196.
• [23]National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology, Non-small Cell Lung Cancer, Version 3. 2012. Available at www.nccn.org webcite
• [24]Arias-Pulido H, Smith HO, Joste NE, Bocklage T, Qualls CR, Chavez A, Prossnitz ER, Verschraegen CF: Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol Oncol 2009, 114(3):480-485.
• [25]Saliba D, Elliott M, Rubenstein LZ, Solomon DH, Young RT, Kamberg CJ, Roth C, MacLean CH, Shekelle PG, Sloss EM, et al.: The vulnerable elders survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 2001, 49(12):1691-1699.
• [26]Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383.
• [27]Min L, Yoon W, Mariano J, Wenger NS, Elliott MN, Kamberg C, Saliba D: The vulnerable elders-13 survey predicts 5-year functional decline and mortality outcomes in older ambulatory care patients. J Am Geriatr Soc 2009, 57(11):2070-2076.
• [28]Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, Barbera S, Ferrau F, Piazza E, Rosetti F, et al.: Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003, 95(5):362-372.
• [29]Gridelli C: The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 2001, 1(6 Suppl):4-7.
• [30]Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, et al.: Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 2011, 6(12):2104-2111.
• [31]Huang CH, Williamson SK, Van Veldhuizen PJ, Hsueh CT, Allen A, Tawfik O, Wick J, Smith H, Uypeckcuat AM, Mayo M, et al.: Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 2011, 6(2):372-377.
• [32]Yardley DA, Burris HA 3rd, Markus T, Spigel DR, Greco FA, Mainwaring M, Waterhouse DM, Webb CD, Hainsworth JD: Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer. Clin Breast Cancer 2009, 9(4):237-242.
• [33]Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, et al.: Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clinical cancer research: an official journal of the American Association for Cancer Research 2007, 13(19):5816-5824.
• [34]Matei D, Emerson RE, Schilder J, Menning N, Baldridge LA, Johnson CS, Breen T, McClean J, Stephens D, Whalen C, et al.: Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Cancer 2008, 113(4):723-732.
• [35]Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, Heldin CH, Rubin K: Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001, 61(7):2929-2934.
• [36]Baluk P, Hashizume H, McDonald DM: Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005, 15(1):102-111.
• [37]Hellstrom M, Gerhardt H, Kalen M, Li X, Eriksson U, Wolburg H, Betsholtz C: Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 2001, 153(3):543-553.
• [38]Sennino B, Falcon BL, McCauley D, Le T, McCauley T, Kurz JC, Haskell A, Epstein DM, McDonald DM: Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res 2007, 67(15):7358-7367.
• [39]Lu C, Shahzad MMK, Moreno-Smith M, Lin Y, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, et al.: Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther 2010, 9(3):176-182.
• [40]Falcon BL, Pietras K, Chou J, Chen D, Sennino B, Hanahan D, McDonald DM: Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B. Am J Pathol 2011, 178(6):2920-2930.
• [41]Servidei T, Riccardi A, Sanguinetti M, Dominici C, Riccardi R: Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation. J Cell Physiol 2006, 208(1):220-228.
• [42]Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, Whitehead M, Spaans JN, Graham BC, Goss GD, et al.: Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2008, 26(1):54-59.
• [43]Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, et al.: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006, 12(8):908-916.
• [44]Birim O, Maat AP, Kappetein AP, van Meerbeeck JP, Damhuis RA, Bogers AJ: Validation of the Charlson comorbidity index in patients with operated primary non-small cell lung cancer. European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery 2003, 23(1):30-34.
• [45]Retornaz F, Monette J, Batist G, Monette M, Sourial N, Small D, Caplan S, Wan-Chow-Wah D, Puts MT, Bergman H: Usefulness of frailty markers in the assessment of the health and functional status of older cancer patients referred for chemotherapy: a pilot study. The journals of gerontology Series A, Biological sciences and medical sciences 2008, 63(5):518-522.
• [46]Mohile SG, Bylow K, Dale W, Dignam J, Martin K, Petrylak DP, Stadler WM, Rodin M: A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer 2007, 109(4):802-810.
• [47]Lilenbaum R, Rubin M, Samuel J, Boros L, Chidiac T, Seigel L, Dowlati A, Graham P, Beaumont J, Du H: A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 2007, 2(4):306-311.
• [48]Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, et al.: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2004, 22(2):330-353.
• [49]Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavole A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, et al.: Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011, 378(9796):1079-1088.